Haemostatix Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.haemostatix.com
Clinical Trials
5
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)PeproStat as a Topical Agent Used to Stop Bleeding in Patients Undergoing Surgery
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Haemostatix Ltd
- Target Recruit Count
- 169
- Registration Number
- NCT03131336
- Locations
- 🇧🇦
University Clinical Hospital, Bolnicka 25, Sarajevo, Bosnia and Herzegovina
🇭🇷University Clinical Hospital Centre "Sestre Milosrdnice", Vinogradska cesta 29, Zagreb, Croatia
🇵🇱Klinika Neurochirurgii Gdanskie Centrum Kliniczne, ul. Dębinki 7, Gdańsk, Poland
PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Haemostatix Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT02204930
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Addenbrooke's University Hospital, Cambridge, United Kingdom
🇬🇧Kings University Hospital, London, United Kingdom
News
No news found